Malaria

Elizabeth A Ashley, Aung Pyae Phyo, Charles J Woodrow

Following unsuccessful eradication attempts there was a resurgence of malaria towards the end of the 20th century. Renewed control efforts using a range of improved tools, such as long-lasting insecticide-treated bednets and artemisinin-based combination therapies, have more than halved the global burden of disease, but it remains high with 445 000 deaths and more than 200 million cases in 2016. Pitfalls in individual patient management are delayed diagnosis and overzealous fluid resuscitation in severe malaria. Even in the absence of drug resistance, parasite recurrence can occur, owing to high parasite densities, low host immunity, or suboptimal drug concentrations. Malaria elimination is firmly back as a mainstream policy but resistance to the artemisinin derivatives, their partner drugs, and insecticides present major challenges. Vaccine development continues on several fronts but none of the candidates developed to date have been shown to provide long-lasting benefits at a population level. Increased resources and unprecedented levels of regional cooperation and societal commitment will be needed if further substantial inroads into the malaria burden are to be made.

Introduction

Malaria is a vector-borne parasitic tropical disease found in 91 countries worldwide. Of more than 120 Plasmodium species infecting mammals, birds, and reptiles, only six are known to infect human beings regularly. Plasmodium falciparum produces high levels of blood-stage parasites that sequester in critical organs in all age groups and cause severe anaemia in African children, in whom the vast majority of malaria deaths occur. Plasmodium vivax usually produces milder disease, but can be severe, and recurrent episodes bring significant associated morbidity. Plasmodium malariae, and the morphologically indistinguishable sympatric species Plasmodium ovale curtisi and Plasmodium ovale wallikeri are understudied, but severity of illness is generally similar to uncomplicated vivax malaria. Plasmodium knowlesi is a primarily zoonotic infection encountered in southeast Asia that can cause severe malaria.

Epidemiology

Malaria is a disease of tropical and subtropical regions, having been eradicated from temperate countries steadily over the last 100 years. It is transmitted by the bite of the female Anopheles mosquito. Disease incidence depends on environmental suitability for local vectors in terms of altitude, climate, vegetation, and implementation of control measures, and hence is inextricably linked to poverty, natural disasters, and war. Less common transmission routes are from mother to child, or via blood transfusion, a rare occurrence in non-endemic countries thanks to blood donor screening procedures, but a significant risk in resource-poor settings. Predictions as to the effect of climate change on global malaria distribution in the future vary, but have suggested the population at risk of malaria will increase, in particular in tropical highland areas.

Plasmodium falciparum and P vivax are the predominant species worldwide with an estimated incidence of 207 million and 8.5 million cases respectively in 2016. The great majority of falciparum malaria occurs in sub-Saharan Africa (approximately 190 million cases) where transmission remains intense in many locations, although there is considerable variation in incidence within and between countries. Vivax malaria is much less common in this region because the human population is largely Duffy antigen negative (see predisposing factors below). In Asia and Oceania, malaria case numbers are generally lower and proportions caused by P vivax and P falciparum are similar, whereas in the Americas, vivax malaria cases exceed falciparum by more than two times.

P malariae and P ovale have a global distribution but incidence is low with P ovale found mainly in Africa and southeast Asia. Macaques are the natural hosts of P knowlesi. In Malaysia, which has a high burden of knowlesi malaria, cases were initially misdiagnosed as P malariae because of morphological similarities when examined by light microscopy. The true global burden of disease is unknown; however, although this parasite is capable of being transmitted by Anopheles dirus, an important vector of human malaria, it is predominantly a zoonosis. Human infections with other simian malarias such as Plasmodium cynomolgi and Plasmodium simium can occur. They are assumed to be infrequent events with the caveat that routine microscopic examination could fail to distinguish these from the more common species.
The human phases of the malaria life cycle are shown in figure 1. Sporozoites are inoculated by the bite of an infected female *Anopheles* mosquito. The parasite undergoes a pre-erythrocytic liver stage which typically lasts for 1–2 weeks before the onset of the blood stage, where serial cycles of asexual replication produce rising parasite numbers and hence human disease. A sub-population of intraerythrocytic parasites switches to sexual development, producing female and male gametocytes. These distinctive transitional stages transmit malaria to the mosquito via a blood meal. Male gametocytes exflagellate in the mosquito midgut and male and female gametes fuse to form a zygote that transforms into a mobile ookinete and passes through the gut wall. The oocyst releases sporozoites which migrate to the mosquito salivary glands, completing the lifecycle.

In *vilax* and *ovale* infections, a proportion of sporozoites become dormant hypnozoites, causing relapses months or years after the initial infection.

**Pathogenesis**

Symptoms of malaria develop once the erythrocytic cycle produces a parasitaemia above a certain threshold (roughly 100 parasites per µL). Incubation periods are typically 10–14 days for *P falciparum* or *P knowlesi*, 2–3 weeks for *P vivax* and *P ovale*, and 18 days or longer for *P malariae*; however, there is variation—eg some strains of *P vivax* have a 3–6 month primary incubation period. Classic accounts describe periodic fever spikes at intervals corresponding to the erythrocytic cycle length of the infecting species (48 h for *P falciparum*, *vilax*, or *ovale* and 72 h for *P malariae*), resulting from synchronisation of developmental stages, but such patterns are now observed rarely. *P falciparum* is unique in that erythrocytes containing mature parasites sequester inside small and medium-sized vessels, avoiding parasite clearance in the spleen but causing host endothelial cell injury and microvascular obstruction. Cytodherence is mediated by *P falciparum* erythrocyte membrane protein 1 (PFEMP1), a clonally variant set of proteins exported to the infected erythrocyte surface and encoded by the var gene family. Subtypes of PFEMP1 bind to different endothelial receptors; for example, those that bind intercellular adhesion molecule-1 and endothelial protein C receptor are associated with cerebral malaria. Infected erythrocytes also bind to uninfected cells (rosetting), and uninfected cells become less deformable, exacerbating microvascular obstruction.

The clinical effect of sequestration and associated endothelial dysfunction depends on the organ(s) involved. In the brain, it contributes towards coma, in the lungs it predisposes to respiratory failure, and in pregnant women, sequestration in the intervillous space of the placenta leads to placental malaria with the consequences of maternal anaemia, low birthweight, preterm labour, and increased risk of abortion and stillbirth. Placental cytoadherence is mediated by binding to chondroitin sulphate A (CSA), specifically via the PfEMP1 variant VAR2CSA, and the effects are most severe in primigravid women. Anaemia is a common feature of malaria and is typically multifactorial in origin with red cell loss as the leading
The most common manifestations of severe malaria are cerebral malaria, acute lung injury, which can progress to acute respiratory distress syndrome (in up to 25% of cases), acute kidney injury, typically presenting as acute tubular necrosis, and acidosis. Lactic acid predominates but other acids have been identified in adults with severe malaria, including hydroxyphenyllactic acid, and α-hydroxybutyric and β-hydroxybutyric acids. Severe anaemia (without major organ dysfunction) is a common presentation in children. Other differences in disease presentation in children compared with adults are more frequent seizures (in 60–80%), hypoglycaemia, and concomitant sepsis, and less frequent pulmonary oedema and renal failure. The case fatality rate of treated cerebral malaria is usually 10–20% and can reach 50% in pregnant women. Coma can be profound with extensor posturing, positive pout reflex, and teeth-grinding. Neuroimaging typically shows some evidence of brain swelling but this is less prominent in adults than in children, in whom brain swelling is strongly associated with a fatal outcome. Characteristic fundoscopic findings in cerebral malaria include retinal whitening, changes in blood vessel colour, and haemorrhages. Papilloedema is unusual. Two patterns of acute kidney injury are described in malaria: one in patients with severe malaria with multiorgan failure and the second in patients who have been successfully treated and do not have evidence of other organ involvement.

**Laboratory diagnosis**
Confirming the presence of parasites in all malaria cases ensures species-specific antimalarial treatment and points to other illnesses in negative cases. The gold standard for malaria diagnosis remains light microscopy of stained blood films, thick films providing sensitivity and thin films allowing speciation and quantitation (figure 2). However, rapid diagnostic tests (RDTs) now predominate as the first-line investigation with a wide range of devices available. Given the distribution of species, in much of Africa a *P falciparum*-only test based on the highly expressed histidine-rich protein 2 (PfHRP2) antigen is often used; this can remain positive for several weeks after parasite clearance because of persisting (once-infected) red blood cells. Elsewhere, RDTs often incorporate both an HRP2-detecting strip for sensitive falciparum detection and a pan-species strip that detects the lactate dehydrogenase enzyme of all human malarias, although this is relatively insensitive for *P knowlesi* diagnosis. In Latin America, HRP2 gene deletions mean that HRP2-based tests are unreliable, and evidence is emerging that the problem could extend to Africa. Very high falciparum parasitaemias can also produce negative results due to the prozone effect.

---

**Panel 1: Diagnostic criteria for severe malaria**

**Clinical criteria**
- Prostration
- Confusion or agitation (with Glasgow Coma Scale [GCS] >11)
- Coma (GCS <11 or Blantyre Coma Scale <3 in children)
- Respiratory distress (acidotic breathing)
- Convulsions
- Shock: prolonged capillary refill time (>2 s), with or without systolic blood pressure <80 mm Hg in adults (<70 in children)
- Pulmonary oedema (should be confirmed radiologically)
- Abnormal bleeding
- Jaundice
- Anuria
- Repeated vomiting

**Laboratory criteria**
- Haemoglobin <7 g/dL in adults, <5 g/dL in children
- Haemoglobinuria
- Hypoglycaemia (blood glucose <2.2 mmol/L or <40 mg/dL)
- Acidosis (ie, base deficit >8 meq/L or plasma bicarbonate <15 mmol/L or venous plasma lactate >5 mmol/L)
- Acute kidney injury (creatinine >3 mg/dL or urea >20 mmol/L)
- Asexual parasitaemia >10% of infected red blood cells (Note: national guidelines can vary—eg, UK parasitaemia cutoff is 2%)
- Anuria
- Repeated vomiting
The threshold of detection for these standard methods is approximately 50 parasites per µL (microscopy) and 200 parasites per µL for PfHRP2-based \textit{Pf}alciparum RDTs (several times higher for non-falciparum RDTs). Nucleic acid amplification-based tests provide much greater sensitivity (often below one parasite per µL).33

Case management
The treatment of malaria, particularly that of \textit{Pf}alciparum, was revolutionised by the introduction of the artemisinin derivatives in the 1990s, a group of semisynthetic compounds produced from \textit{qinghaosu} (artemisinin), a natural product of the sweet wormwood plant (\textit{Artemisia annua}). Artemisinins are rapidly effective, safe, and well tolerated. Their discovery by China’s Project 523 was acknowledged by the award of the 2015 Nobel Prize to Tu Youyou.

Management of severe malaria
All patients diagnosed with severe malaria, including women in all trimesters of pregnancy, should receive parenteral artesunate without delay (panel 2).20 A higher mg/kg bodyweight dose of artesunate is given to children weighing less than 20 kg. Artesunate was shown to be vastly superior to quinine in large trials (35% [95% CI 18·5–47·6] mortality reduction in southeast Asian adults and 22% [95% CI 8·1–36·9] reduction in African children).34,35 If quinine is prescribed, a loading dose must be given and the second dose administered 8 h after the start of the first infusion.36 Intramuscular artemether is another option but was inferior to parenteral artesunate for preventing malaria deaths in Asian adults.37 Parenteral quinidine is still recommended as an alternative treatment in the USA but is associated with substantial cardiotoxicity. Hypoglycaemia (blood glucose <2·2 mmol/L) is a serious complication of malaria and is aggravated by quinine therapy, especially in pregnant women. Management of hypovolaemia and acidosis requires cautious fluid replacement with crystalloids to reduce the risk of pulmonary oedema.38 The dangers of overly aggressive volume replacement have been shown in adults and children. In the multicentre FEAST study of more than 3000 critically ill African children with
sepsis and impaired perfusion, more than half (57%) of whom had malaria, those given fluid boluses had a higher mortality at 48 h than those who were not (relative risk [RR] for bolus vs control, 1.45; 95% CI, 1.13–1.86). Severe anaemia (haemoglobin <50 g/L) requires urgent correction but evidence regarding optimal transfusion practices is absent. A trial is ongoing to define this in children.24,40,41 Seizures should be controlled with benzodiazepines; if recurrent, loading with longer-acting anticonvulsants should be considered with close monitoring for respiratory depression. Routine seizure prophylaxis with phenobarbital given to Kenyan children with cerebral malaria in a placebo-controlled trial was associated with increased rates of respiratory depression and death.42 Other supportive measures depend on the clinical manifestations and the level of care available. Early renal replacement therapy is recommended. If there is no access to endotracheal intubation, a nasogastric tube should be passed but enteral feeding delayed for 72 h to reduce the risk of aspiration pneumonia.43

Patients with cerebral malaria should have blood cultures taken, a lumbar puncture performed, and broad-spectrum antibiotics commenced, pending negative culture results and clinical improvement. Severe malaria is associated with concomitant bacterial sepsis, with non-typhoidal *Salmonella* bacteraemia described frequently in African children.44 Co-infections with other tropical diseases are unusual in travellers but more common in hyperendemic countries.

Patients with severe malaria should have frequent monitoring of vital signs, level of consciousness, glucose, renal function, and haemoglobin. Monitoring parasite density (every 6–12 h) confirms parasite clearance (typically within 72 h) but clinical improvement often takes considerably longer.45,46 Once the patient is conscious, able to eat and drink, and has received at least 24 h of parenteral therapy, oral follow-on treatment with an artemisinin-based combination treatment is advised.

**Adjunctive therapies for severe malaria**

Various adjunctive therapies have been evaluated without success in terms of improving the outcome from severe malaria, including steroids, anti-TNF, mannitol, N-acetylcysteine (antioxidant properties), exchange transfusion, and levamisole (inhibitor of sequestration).47–49

**Severe vivax and knowlesi malaria**

Severe vivax malaria tends to occur in patients with comorbidities in endemic countries and has not been observed frequently in returned travellers. Respiratory failure and acute kidney injury have been reported repeatedly in fatal cases.50,51 One of the most common manifestations of severe vivax malaria in children is respiratory distress.52 Coma is a rare occurrence in patients with vivax parasitaemia.53 The main burden of serious morbidity and mortality from vivax malaria is secondary to severe anaemia, with young children particularly vulnerable. Rates of hospital admission and death from vivax malaria approach those for falciparum malaria in some parts of the world such as Papua in Indonesia.52,53 Severe knowlesi malaria is associated with high parasite densities and similarly can present as acute kidney injury, shock, or respiratory failure.54

---

**Panel 2: Drug treatment of malaria**

**Severe malaria**

**Initial treatment**

- Intravenous artesunate (2–4 mg/kg per dose hours 0, 12, and 24; then every 24 h; in patients with bodyweight <20 kg unit dose is 3–0 mg/kg)

**Alternatives**

- Intravenous quinine infusion; loading dose of 20 mg/kg (given over 4 h) at admission then 10 mg/kg (given over 2 h) every 8 h
- Intramuscular artemether injection: 3·2 mg/kg initial dose, then 1·6 mg/kg every 24 h

**Once able to eat and drink**

- Oral treatment with an artemisinin-based combination therapy (ACT) for 3 days (not mefloquine due to increased risk of post-malaria neurological syndrome)

**Uncomplicated malaria**

Uncomplicated *Plasmodium falciparum* or *Plasmodium knowlesi* malaria

- Artether–lumefantrine 1·4–4 mg/kg of artemether and 10–16 mg/kg of lumefantrine twice daily for 3 days with food containing fat, or
- Dihydroartemisinin–piperaquine 4 mg/kg of dihydroartemisinin and 18 mg/kg of piperaquine once daily for 3 days (children with bodyweight <25 kg should receive at least 2·5 mg/kg per day of dihydroartemisinin and 20 mg/kg per day piperaquine), or
- Artesunate 4 mg/kg per day with mefloquine 8 mg/kg per day for 3 days, or
- Artesunate 4 mg/kg per day with amodiaquine 10 mg base/kg per day for 3 days, or
- Artesunate 4 mg/kg per day for single dose sulfadoxine–pyrimethamine (25 mg/kg–1·25 mg/kg) Chloroquine-sensitive *Plasmodium vivax*, *Plasmodium ovale*, *Plasmodium malariae*:
- Chloroquine 10 mg base/kg per day at hour 0 and hour 24 followed by 5 mg base/kg at hour 48

*Target doses and full dosing information of different formulations and non-artemisinin-based treatment options are shown in the appendix. Choice of ACT to treat *Pl. falciparum* depends on local resistance patterns; mefloquine is contraindicated in patients with a history of epilepsy or neuropsychiatric disorders. *Chloroquine-resistant* *P. vivax* is treated with one of the ACTs (except artesunate plus sulfadoxine–pyrimethamine). Initial treatment of *P. falciparum* depends on local resistance patterns; mefloquine is contraindicated in patients with a history of epilepsy or neuropsychiatric disorders. Initial treatment of *P. vivax* or *P. ovale* should be followed by a course of primaquine to prevent relapse, if no contraindications (glucose-6-phosphate-dehydrogenase deficiency, pregnancy, age >6 months).*
The main considerations when prescribing antimalarials are the infecting species and the risk of drug resistance. Comprehensive, evidence-based guidelines for the treatment of uncomplicated malaria are available on the WHO website. Given the global spread of *P falciparum* resistant to chloroquine and antifols, artemisinin-based combination treatments (ACTs) are recommended for the treatment of falciparum malaria or falciparum mixed with non-falciparum species, except in the first trimester of pregnancy (see appendix). ACTs consist of a combination of an artemisinin derivative that rapidly reduces parasitaemia and a partner drug that removes residual parasites over a longer period. These properties make them the drugs of choice to treat knowlesi malaria as well. The leading ACTs in use are artemether–lumefantrine, artesunate–amodiaquine, dihydroartemisinin–piperazine, artesunate–mefloquine, and artesunate plus sulfadoxine–pyrimethamine. The first four ACTs on this list exist as fixed-dose combinations, with paediatric formulations available. Artemether–lumefantrine should be given with milk or food containing fat to enhance lumefantrine absorption. The ACTs were highly efficacious against all *P falciparum* until recently when numbers of treatment failures increased in parts of southeast Asia (figure 3).

Atovaquone–proguanil is an alternative non-artemisinin-based treatment that is useful for individual patients (eg, returned travellers without hyperparasitaemia, or in combination with artesunate plus primaquine for patients in endemic countries who have failed treatment with standard ACTs); however, it is not recommended for widespread implementation in endemic countries, because of the propensity for rapid emergence of atovaquone resistance.

Quinine remains efficacious, although it requires a long course of treatment, is poorly

---

**Figure 3:** Global distribution of drug-resistant *Plasmodium falciparum*

Countries are shown according to the level of resistance of local *P falciparum*; the 13 countries approaching elimination (as defined in the World Malaria Report 2016) are also shown. The inset graphs show WHO estimates of global annual malaria case numbers and deaths from 2000 to 2015 (with 95% upper and lower uncertainty intervals). ACT=artemisinin-based combination therapy. Created with mapchart.net ©.
tolerated, particularly by children, and needs to be combined with a second agent such as doxycycline or clindamycin.

Uncomplicated vivax, malariae, and ovale malaria are treated with chloroquine, unless chloroquine-resistant *Plasmodium vivax* is likely (Indonesia, Oceania) when an ACT is used (panel 2). This should be followed by primaquine to eradicate dormant hypnozoites.

The decision to admit a patient with uncomplicated malaria to hospital will depend on the setting and local guidelines. It is common practice to admit non-immune returned travellers for an initial period of observation until clinical improvement and a fall in parasitaemia are observed.

**Management of uncomplicated malaria in pregnancy**
Early detection of malaria in pregnancy is vital. Uncomplicated falciparum malaria in the first trimester is treated with a 7-day course of quinine and clindamycin. Safety data of first trimester ACT use have been reviewed and are reassuring, and treatment guidelines will be reviewed in the near future. After week 12 of gestation, treatment is as for non-pregnant patients. Vivax malaria in pregnancy is treated with chloroquine unless resistance is suspected (when quinine should be given), but radical cure with primaquine is contraindicated as the glucose-6-phosphate-dehydrogenase (G6PD) status of the foetus cannot be ascertained. The pharmacokinetic properties of several antimalarial drugs are different in pregnancy with a tendency towards lower drug exposure. This makes treatment failure more likely, especially in non-immune women.

**Congenital malaria**
The diagnosis of congenital malaria is easy to miss, especially if the mother is asymptomatic. The clinical presentation mimics neonatal sepsis. Parenteral treatment (artesunate or quinine) should be given for at least the first dose in congenital falciparum malaria. Follow-on treatment is with an ACT. Congenital vivax malaria can be treated with oral chloroquine unless the infant is very unwell, in which case parenteral drugs should be used, or if chloroquine resistance is likely, then either an ACT or quinine should be given.

**Adjunctive primaquine therapy**
To reduce the risk of relapse from dormant hypnozoites in the liver, a course of the 8-aminoquinoline primaquine is added to the treatment of vivax or ovale malaria. Primaquine causes dose-dependent haemolytic anaemia in patients with G6PD deficiency, hence testing for this enzymopathy is recommended; however, worldwide, access to testing is poor. The standard primaquine treatment regimen is long (14 days) and, as a result, difficult to adhere to. Doubling the daily dose to 1 mg base/kg bodyweight and shortening the course to 7 days was shown to result in an increased risk of clinically significant haemolysis in G6PD heterozygotes (9/17 [53%] patients had >25% fractional haematocrit reduction compared with 2/16 [3%] G6PD heterozygotes taking the standard 0·5 mg/kg dose for 14 days; p=0·022). Failure of primaquine to suppress relapses has been linked to reduced metabolism of the drug in individuals with polymorphisms in the cytochrome P-450 isoenzyme 2D6. The longer-acting 8-aminoquinoline tafenoquine is currently under review by stringent regulatory authorities to replace primaquine for radical cure as a single dose treatment but the risk of haemolysis remains.

Primaquine is the only drug able to kill mature (stage V) gametocytes of *P falciparum*. In endemic areas, prescription of a single low (0·25 mg/kg) dose of primaquine with an ACT is recommended to reduce the risk of onward transmission. This dose is considered safe in G6PD deficiency.

**Safety of the antimalarial drugs**
Antimalarials can have serious side-effects and the frequency with which they occur varies between populations. Important examples include quinidine-induced cardiotoxicity, hypoglycaemia, and hypotension following quinine, which can also cause QT-prolongation, although much less frequently than following quinidine, hepatotoxicity and cutaneous hypersensitivity reactions to sulfadoxine–pyrimethamine (Stevens-Johnson syndrome in approximately 1/10000 recipients), and neuro-psychiatric reactions to mefloquine (approximately 1/200–1/2000 at treatment doses).

**Treatment failure**
Malaria treatments are not always curative. Treatment failure usually presents as a recurrence of symptoms with detectable parasitaemia 2–6 weeks after an apparently successful treatment and is not always due to drug resistance. Alternative explanations include high parasite densities (particularly in non-immune individuals), poor drug bioavailability, non-adherence to therapy, and falsified or substandard antimalarials. Relapse of vivax malaria is common after an episode of falciparum in southeast Asia (roughly 30% of cases).

**Artemisinin-resistant falciparum malaria in southeast Asia**
Like combination treatments in other areas of medicine, ACTs were introduced to prevent or delay development of resistance in a population over time. After more than a decade of use in southeast Asia, artemisinin resistance was confirmed, manifested by a phenotype of delayed parasite clearance. Use of artemisinin monotherapies was probably a contributing factor. The loss of the rapid parasitidical effect of the artemisinin derivatives led predictably to worsening partner drug resistance (to mefloquine and piperaquine) and reduced efficacy of the corresponding ACTs. Artemether–lumefantrine efficacy was poor in Cambodia in the early 2000s and has not
been reassessed since then. Molecular markers for parasite resistance to many of the commonly used drugs have been discovered.7–20 High rates of ACT failure have now been reported from Cambodia, Thailand, and Vietnam.81–83 A newer ACT, artesunate–pyronaridine, is likely to be approved for use in these countries in the near future. Triple artemisinin-based combinations (dihydroartemisinin–piperaquine with mefloquine and artemether–lumefantrine with amodiaquine) are being evaluated in an attempt to bridge the gap until new medicines become available.84

### New antimalarial drugs

Investment in antimalarial drug discovery and development, with the creation of product development partnerships in the early 2000s, have revitalised a near empty drug pipeline. Most of the drugs under development are blood schizontocides with a few exceptions.85–91 There are efforts to develop alternative transmission-blocking drugs as an elimination tool.92

### Complications of malaria

Delayed haemolytic anaemia can follow artemisinin treatment of travellers with falciparum malaria.93 The key event appears to be pitting, a splenic process whereby ring-stage parasites killed by artemunate are expelled from their host erythrocytes which return to the circulation, but with a reduced lifespan (figure 1).94 This explains why the diagnostic antigen PfHRP2 persists for weeks after artemisinin treatment (it is exported to the erythrocyte periphery); indeed PfHRP2 concentration following parasite clearance predicts later haemolysis.95 Treatment with quinine and other slow-acting drugs allows unhindered development of parasites until sequestration, so haemoglobin falls early. Delayed haemolysis can hence be considered a predictable event related to the early beneficial effect of artemisinins.96 The problem appears to be somewhat less in African children,97 presumably because of developing immunity, although cases have been documented.98 It has also been suggested that post-artesunate delayed haemolysis could contribute to the high frequency of haemoglobinuria reported in eastern Uganda recently.99

Other haematological complications of malaria include hyper-reactive malarial splenomegaly (HMS), and rarely, splenic rupture. HMS is characterised by massive splenomegaly, raised IgM antimalarial antibodies, and anaemia. It responds to a prolonged course of weekly treatment with antimalarial drugs at prophylactic doses.100

Neurological complications following an episode of severe malaria range from a reversible post-malaria neurological syndrome to permanent deficits including visual, motor, or language disorders and epilepsy. In a study of African children with severe falciparum malaria, the prevalence of persistent neurological sequelae in the 4898 children who survived was 3·2%.101 P malariae can be complicated by anaemia and the nephrotic syndrome.102

### Malaria co-infection with HIV

HIV co-infection increases malaria severity and parasite densities tend to be higher. Co-trimoxazole prophylaxis is protective against malaria and concomitant antifolate antimalarial drugs should be avoided.103 There are drug–drug interactions between common antimalarials and antiretroviral drugs—eg, efavirenz increases amodiaquine exposure and the risk of toxicity so these drugs should not be coadministered. Efavirenz decreases lumefantrine exposure but no formal recommendations have been made to adjust the dose.104

### Immunity

Repeated exposure over a long period to malaria leads to premunition—protection from disease but ongoing blood stage infection. In P falciparum this involves sequential acquisition of antibodies to PfEMP1 subtypes. Asymptomatic falciparum or vivax parasitaemia are common in areas of high endemicity and use of more sensitive molecular detection methods for malaria has revealed that parasites can persist for years longer than thought possible previously.105 Antibodies act on parasite blood stages to inhibit replication with complement fixation thought to play a part.106 Antigen presentation takes place at different stages of the parasite lifecycle and T cells regulate both liver and blood stages of infection.107 Immunity is lost steadily after an individual leaves an endemic area, or in a population with falling transmission.

### Predisposing and protective factors

A wide range of inherited and acquired factors influence an individual’s chance of infection and severe illness with malaria (panel 3). Haldane’s hypothesis suggesting that inherited human red cell conditions reflect evolutionary
Panel 4: Strategies to prevent malaria in different target groups

**Chemoprophylaxis**

**Intermittent preventive treatment**
- Pregnant women receive sulfadoxine–pyrimethamine (SP) at all antenatal care visits from second trimester (minimum dose interval of 1 month)
- Infants in moderate transmission areas receive SP with routine immunisations

**Seasonal malaria chemoprevention**
- Children aged 3–59 months in areas of seasonal transmission in the Sahel (intermittent SP plus amodiaquine at treatment doses, maximum four courses)

**Fixed-term**
- Travellers (atovaquone–proguanil, doxycycline, mefloquine, or primaquine)
- HIV-infected patients receiving co-trimoxazole as prophylaxis for opportunistic infections are protected against malaria

**Vaccination**
- RTS,S/AS01 in children (four doses for children aged 5–17 months) is the only registered malaria vaccine (still under evaluation)

**Vector control or bite prevention**
- Long-lasting insecticide-treated bednets: most effective in high-transmission areas where vectors rest indoors at night
- Indoor residual spraying (with insecticides)
- Repellents (topical and spatial): convincing protective effect not shown

Malaria and other Plasmodium species preferentially invade reticulocytes via their Duffy binding protein. This protection has turned out not to be absolute; reports of vivax malaria in Duffy-negative individuals indicate that alternative ligands can mediate invasion. Nevertheless, clinical vivax malaria remains rare in countries where the population is completely Duffy negative (most of sub-Saharan Africa).

Other families of red cell surface proteins also influence malaria infection, with individuals with blood group O relatively protected against severe falciparum malaria and those with group B at higher risk. In 2017, a complex rearrangement in the polymorphic MNS blood group system (the DUP4 haplotype) producing hybrid glycoprotein proteins was shown to be associated with protection against severe malaria in east Africa.

**Prevention of malaria**

Malaria is prevented by chemoprophylaxis, vaccination, bite-avoidance and vector-control measures (panel 4).

**Chemoprophylaxis**

Target groups for chemoprophylaxis are pregnant women, young children, and travellers. Intermittent preventive therapy in pregnancy (IPTp) and infants has been slow to be scaled up in many areas and their impact is threatened by sulfadoxine–pyrimethamine resistance. The use of alternative antimalarials such as dihydroartemisinin–piperaquine is under evaluation. Intermittent screening and treatment of pregnant women has not been demonstrated to be an effective alternative strategy to IPTp, attributed to lack of sensitivity of existing RDTs to detect malaria in pregnancy. Seasonal malaria chemoprevention in children with sulfadoxine–pyrimethamine plus amodiaquine has been adopted widely and has reduced malaria in areas of highly seasonal transmission in the Sahel.

To prevent malaria in travellers, the choice of chemoprophylaxis should consider the risks of malaria and drug resistance, which should be balanced with the risk of drug toxicity. Atovaquone–proguanil and doxycycline are prescribed as prophylaxis frequently. Weekly mefloquine at prophylactic doses is a convenient option but unpopular owing to concerns about neurotoxicity. Primaquine is a highly effective causal prophylactic agent with the added advantage of enhanced protection against vivax malaria (hypnozoites stages) but requires exclusion of G6PD deficiency.

**Vaccine development**

Malaria subunit vaccines are designed to provide immunity against proteins exposed at critical stages of the lifecycle. Targeting sporozoite stages via one of the surface proteins that mediate homing to the liver and host cell traversal or invasion aims to reduce frequency of infection. The RTS,S/AS01 vaccine based on *P falciparum* circumsporozoite protein is the most studied vaccine.
In a landmark study in African children, RTS,S/AS01 provided significant protection against falciparum malaria infection over a 3–4 year period; in older children, vaccine efficacy was 36.3% (95% CI 31.8–40.5) with a 20-month booster and 28.3% (95% CI 23.3–32.9) without. However, efficacy was relatively lower (25.9% [95% CI 19.9–31.5] with booster and 18.3% [95% CI 11.7–24.4] without) in very young children (6–12 weeks old at first dose). Further, in contrast to earlier data, RTS,S/AS01 did not provide even efficacy across all strains. Longer-term follow-up at one centre revealed a higher incidence of malaria in later years in vaccinated children with higher-than-average exposure to malaria. An overall reduction in long-term mortality remains to be demonstrated. WHO is supporting pilot implementation of the four-dose regimen in children aged 5–17 months in three countries, allowing study of long-term outcomes, safety, and feasibility.

A contrasting approach to producing sporozoite-based immunity is the P. falciparum sporozoite (PfSPZ) vaccine, an intravenous injection of irradiation-attenuated sporozoites. PfSPZ has now entered clinical trials in Africa; again the challenges are likely to centre on obtaining durable protection against all relevant strains.

The use of merozoite-stage proteins as vaccine targets aims to reduce asexual replication rate and hence protect against disease rather than produce sterile immunity, potentially allowing immunity to develop naturally while the vaccinee is protected from severe disease. Of the various extracellular merozoite proteins that collectively mediate erythrocyte invasion by P. falciparum, there is considerable interest in targeting PfRh5 since its binding to the Ok blood group antigen basigin is critical for erythrocyte invasion. Another asexual stage vaccine targets the product of the PfEMP1 VAR2CSA type aiming to prevent parasitised cell binding to CSA1 and hence protect against placental malaria.

Transmission-blocking vaccines against sexual-stage antigens aim to generate antibodies that are ingested in the mosquito blood meal, potentially providing immunity at a population level. There is also increasing study of how vaccine responses to multiple targets might synergise to provide higher levels of overall protection, although such an approach is likely to increase costs substantially. Vaccine development overall is complicated by the absence of reliable laboratory correlates of immunity.

Vector control

More than 40 species of Anopheles are important malaria vectors. The mainstays of vector control are long-lasting insecticide (pyrethroid) treated bednets (LLINs) and indoor residual spraying with insecticides. LLINs have reduced morbidity and mortality from malaria and have the biggest impact in high transmission areas where vectors bite indoors at night, such as the highly successful Anopheles gambiae complex. Their success is threatened by widespread pyrethroid resistance in anopheline vectors, although the relationship between resistance and LLIN efficacy is not well characterised. Alternative insecticides are needed urgently. In the meantime, addition of the synergist piperonyl butoxide to pyrethroid-treated bednets has been evaluated in some countries with mixed results. WHO have given an interim endorsement to this new class of products but have not recommended widespread deployment. Bite-prevention strategies including topical repellents have not been shown to have an effect on malaria incidence. Other approaches under consideration are mass treatment with ivermectin, which shortens mosquito survival, and transgenic mosquitoes.

From control to elimination

Progress towards malaria elimination is uneven. Indigenous cases in Europe, central Asia (north of Afghanistan), Sri Lanka, and several countries in Latin America are now extremely rare. However, in many sub-Saharan African countries, where transmission is highest, eliminating malaria has proved more difficult and there are signs that progress in this direction has stalled. Areas with civil disruption have experienced substantial increases in malaria, exemplified by Venezuela. Pilot studies of mass drug administration (MDA) of ACT with single-dose primaquine to accelerate elimination of drug-resistant malaria in southeast Asia have taken place and early reports suggest it is effective and safe.

Controversies and uncertainties

There is more to be learned about the pathogenesis of severe vivax malaria, the relationship between pyrethroid resistance and LLIN efficacy, and the longer-term effects of MDA. Elimination of vivax malaria will require increased uptake of primaquine, which means addressing safety concerns in populations where G6PD deficiency is common. Elimination of human knowlesi malaria infections while there is a reservoir of parasites in macaques is another challenge. Whether artesiminisin resistance spreads or pops up in different locations has been the subject of debate; recent evidence suggests both are true. The effect of artesiminisin resistance on artemesunate efficacy in the treatment of severe falciparum malaria is unknown because severe malaria is now rare in southeast Asia. The loss of ring stage susceptibility to artesunate raises the possibility that the treatment advantage over quinine has been eroded. Addition of parenteral quinine to artesunate has been proposed to provide a safety net for patients with presumed artesiminisin resistance but there is no evidence to support this practice.

Future perspectives

More than 130 years have passed since the protozoan cause of malaria was discovered. Over this period, there have been many scientific breakthroughs, with a subset
translating into interventions capable of reducing the burden of disease and death, notably the discovery and development of antimalarial drugs and insecticides.

The progress towards elimination in some countries shows that existing tools can be enough to eliminate malaria if the right conditions are in place: political commitment, access to health care, and adequate human and financial resources. There is evidence that access to high quality ACTs is still much too low (<25%) in some areas.36 The spread of pyrethroid resistance among *Anopheles* vectors and increasing reports of ACT failures in southeast Asia signal that the window of opportunity to eliminate malaria with existing tools might be closing. Increased resources for disease control usually only come in times of crisis, but a concerted effort now could capitalise on recent gains and accelerate progress towards elimination.

**Contributors**

EAA performed the literature search. EAA and CJW wrote the first draft of text. APP drafted the tables and panels and figure 3. All authors reviewed and approved the final version of the manuscript.

**Declaration of interests**

We declare no competing interests.

**Acknowledgments**

We thank Kamolrat Silamut who created figure 2, and our colleagues and collaborators. The Myanmar–Oxford Clinical Research Unit, the Shoklo Malaria Research Unit, and the Mahidol–Oxford Tropical Medicine Research Unit (MORU) are part of the MORU Tropical Health Network, supported by the Wellcome Trust.

**References**


Malaria.

2014; 481. Malar J

cerebral malaria and other severe forms of malaria treated with an artemisinin derivative: an individual patient data meta-analysis. Malar J 2015; 14:

e1002290. 2017; 14:1002290.


2014; 374:2453–64.


2011; 242–53.


2016; 374:2422–33.

2012; 374:2422–33.

2016; 374:2453–64.

2011; 371:973–43.


2011; 361: 970–78.

2013; 286:35-46.

2016; 374:2453–64.


2016; 374:2422–33.


2016; 374:2422–33.

2011; 371:973–43.


© 2018 Elsevier Ltd. All rights reserved.